OMB Approval
OMB Number: 3235-0145
Expires: December 31, 1997
Estimated average burden
hours per response: 14.90
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
BIOPHARMACEUTICS, INC.
---------------------------------------------------
Name of Issuer
COMMON STOCK
---------------------------------------------------
Title of Class of Securities
090646-10-0
---------------------------------------------------
CUSIP No.
JOHN FIGLIOLINI
30 Beach Hill Road
Scarsdale, New York 10583
914-722-0256
----------------------------------------------------
Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications
October 16, 1996
----------------------------------------------------
Date of Event Which Requires Filing of this Statement
If the filing person has previously filed a statement on Schedule
13G to report the acquisition which is the subject of this
Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4),
check the following box: ______
<PAGE>
SCHEDULE 13D
CUSIP No. 090646-10-0
Page 2 of 3 Pages
1. Name of Reporting Person
JOHN P. FIGLIOLINI
2. Check the appropriate box if a member of a Group:
(A)
(B) X
3. SEC USE ONLY
4. SOURCE OF FUNDS
WC/PF/AF
5. Check box if disclosure of legal proceedings is required
pursuant to items 2(d) or 2 (e):
Not applicable.
6. Citizenship or place of organization:
USA
7. Sole Voting Power:
No
8. Shared Voting Power:
Yes - 3,498,937 Shares
9. Sole Dispositive Power:
No
10. Shared Dispositive Power:
Yes - 3,498,937 Shares
<PAGE>
Page 3 of 3 Pages
11. Aggregate Amount Beneficially owned by each reporting
person:
3,498,937 Shares
12. Check box if the aggregate amount in row (11) excludes
certain shares:
Not applicable.
13. Percent of Class represented by amount in Row (11).
8.53%
14. Type of Reporting Person
EP/CO/IN/OO
Dated: October 16, 1996 /S/ JOHN P. FIGLIOLINI
------------------------
JOHN P. FIGLIOLINI
